I'm glad they announced it officially...
I liked this statement:
“As joint pain and loss of limb strength are common aspects of CHIKV induced disease,
these critical findings provide confidence in PPS as a potential world first CHIKV therapy”
--Dr Lara Herrero
- Forums
- ASX - By Stock
- PAR
- Ann: CHIKV study data published in Peer-Reviewed Journal
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
0.00%
!
42.0¢

Ann: CHIKV study data published in Peer-Reviewed Journal, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
42.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $168.9M |
Open | High | Low | Value | Volume |
42.0¢ | 43.5¢ | 41.5¢ | $220.9K | 520.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 40545 | 41.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 6654 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 11738 | 0.420 |
9 | 46047 | 0.415 |
9 | 109800 | 0.410 |
7 | 32461 | 0.405 |
11 | 173197 | 0.400 |
Price($) | Vol. | No. |
---|---|---|
0.425 | 15536 | 5 |
0.430 | 51217 | 8 |
0.435 | 43087 | 7 |
0.440 | 89547 | 5 |
0.445 | 14469 | 3 |
Last trade - 14.51pm 23/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |